| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FEO; OFE; ODFR; OSTS; PDB2; RANK; CD265; OPTB7; TRANCER; LOH18CR1; TRANCE-R |
| Entrez GeneID | 8792 |
| clone | 3A9G2 |
| WB Predicted band size | 66kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Purified recombinant fragment of human TNFRSF11A (AA: extra 30-212) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TNFRSF11A抗体的3篇参考文献示例(文献信息为假设性示例，供格式参考)：
1. **文献名称**: *"Targeting TNFRSF11A (RANK) with a novel monoclonal antibody inhibits osteoclastogenesis and reduces bone metastasis in breast cancer models"*
**作者**: Smith J, et al.
**摘要**: 研究开发了一种靶向TNFRSF11A的单克隆抗体，通过阻断RANK信号通路抑制破骨细胞分化，并在乳腺癌骨转移小鼠模型中显著减少骨破坏和肿瘤生长。
2. **文献名称**: *"TNFRSF11A antibody-based therapy ameliorates inflammation and joint erosion in a murine model of rheumatoid arthritis"*
**作者**: Zhang L, et al.
**摘要**: 该研究利用抗TNFRSF11A抗体阻断RANK-RANKL相互作用，减轻了类风湿性关节炎模型中的滑膜炎症和关节破坏，提示其治疗自身免疫性疾病的潜力。
3. **文献名称**: *"Characterization of a high-affinity anti-TNFRSF11A antibody for detecting RANK expression in human osteosarcoma tissues"*
**作者**: Brown K, et al.
**摘要**: 研究报道了一种高亲和力抗TNFRSF11A抗体，可用于免疫组化检测骨肉瘤组织中RANK的过表达，为肿瘤微环境研究提供了新工具。
4. **文献名称**: *"Therapeutic blockade of TNFRSF11A signaling attenuates pathological cardiac hypertrophy"*
**作者**: Lee S, et al.
**摘要**: 研究发现抗TNFRSF11A抗体通过抑制心肌细胞中RANK依赖性信号通路，减轻压力超负荷诱导的小鼠病理性心脏肥大。
---
**注**：以上文献为示例，实际引用需以真实发表的论文为准。建议通过PubMed或Web of Science以“TNFRSF11A antibody”或“anti-RANK antibody”为关键词检索最新文献。
TNFRSF11A (tumor necrosis factor receptor superfamily member 11A), also known as RANK (receptor activator of nuclear factor kappa-B), is a transmembrane protein that plays a critical role in regulating bone metabolism, immune cell function, and cancer progression. It binds to its ligand RANKL (RANK ligand) to activate downstream signaling pathways, including NF-κB and MAPK, which are essential for osteoclast differentiation, lymph node development, and thermoregulation. Dysregulation of TNFRSF11A/RANK signaling is implicated in osteoporosis, autoimmune diseases, and metastatic bone cancers.
Antibodies targeting TNFRSF11A are valuable tools for both research and therapeutic applications. In research, they are used to detect RANK expression in tissues or cells, block RANK-RANKL interactions to study osteoclastogenesis, or modulate immune responses. Therapeutically, anti-TNFRSF11A antibodies have been explored to inhibit excessive osteoclast activity in bone-loss disorders or to disrupt pro-tumorigenic signaling in cancers. For instance, denosumab, a monoclonal antibody against RANKL, indirectly targets this pathway and is approved for osteoporosis and bone metastases. Direct anti-TNFRSF11A antibodies, though less clinically advanced, hold potential for precision targeting in conditions where RANK overexpression drives pathology. Challenges include optimizing specificity to avoid off-target effects and ensuring balanced modulation of RANK’s dual roles in bone homeostasis and immunity.
×
